Journal
FEBS LETTERS
Volume -, Issue -, Pages -Publisher
WILEY
DOI: 10.1002/1873-3468.14680
Keywords
dihydroorotate dehydrogenase; drug discovery; Mycobacterium tuberculosis; pyrimidine biosynthesis; tuberculosis
Ask authors/readers for more resources
Researchers have characterized the full-length MTB DHODH and discovered the first selective inhibitor. This study has significant implications for drug treatment of tuberculosis.
Mycobacterium tuberculosis (MTB) is the etiologic agent of tuberculosis (TB), an ancient disease which causes 1.5 million deaths worldwide. Dihydroorotate dehydrogenase (DHODH) is a key enzyme of the MTB de novo pyrimidine biosynthesis pathway, and it is essential for MTB growth in vitro, hence representing a promising drug target. We present: (i) the biochemical characterization of the full-length MTB DHODH, including the analysis of the kinetic parameters, and (ii) the previously unreleased crystal structure of the protein that allowed us to rationally screen our in-house chemical library and identify the first selective inhibitor of mycobacterial DHODH. The inhibitor has fluorescence properties, potentially instrumental to in cellulo imaging studies, and exhibits an IC50 value of 43 mu M, paving the way to hit-to-lead process.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available